Table 2.
Associations between HIV status and Receipt of Smoking Cessation Medications among Patients Recruited to the Veterans Aging Cohort Study (N=1722): Results of Bivariate Comparisons and Adjusted Log-Linear Regression Models
| HIV+ (n=814) |
HIV− (n=908) |
Unadjusted relative risk | Adjusted relative risk | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | p-value | RR | (95% CI) | ARR* | (95% CI) | |
| Receipt of Smoking Cessation Medications | |||||||||
| Any medication | 237 | (29) | 323 | (36) | 0.004 | 0.82 | 0.71, 0.94 | 0.90 | 0.76, 1.07 |
| Nicotine | 154 | (19) | 229 | (25) | 0.002 | 0.75 | 0.58, 0.97 | 0.77 | 0.67, 0.89 |
| replacement therapy | |||||||||
| Bupropion | 69 | (8) | 84 | (9) | NS | 0.97 | 0.75, 1.26 | 1.25 | 0.87, 1.80 |
| Varenicline | 12 | (1) | 4 | (0.4) | 0.03 | 3.02 | 0.43, 21.00 | -- | -- |
*
Relative risk of receiving medications for HIV+ relative to HIV- adjusted for age, sex, race/ethnicity, education, income, unhealthy alcohol use, substance use in last year, moderate-severe depression, recent diagnoses for psychiatric disorders, CVD, chronic pulmonary disease and non-AIDS malignancies, VACS Index 2.0, number of inpatient and outpatient visits, contemplation to quit, past quit attempt, and number of cigarettes smoked daily.